Acute Coronary Syndrome Clinical Trial
— ACS-CBTOfficial title:
Internet-based Behavioral Intervention Following Acute Coronary Syndrome: a Randomized Controlled Trial
The aim of this study is to evaluate if an online Cognitive Behavioral Therapy (CBT) protocol customized for patients following Acute Coronary Syndrome (ACS), reduce cardiac anxiety, enhance Quality of Life (QoL), and promote increased physical activity while controlling for caregiver attention, utilizing an active control group receiving internet-based cardiac lifestyle intervention.
Status | Recruiting |
Enrollment | 260 |
Est. completion date | January 31, 2027 |
Est. primary completion date | January 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ACS = 6 months before assessment (type 1 MI STEMI/NSTEMI or unstable angina [UA]) - Age 18 and older - Clinically significant cardiac anxiety that leads to distress and/or interferes with daily life (Cardiac Anxiety Questionnaire; CAQ: =18 - Able to read and write in Swedish Exclusion Criteria: - Heart failure New York heart Association class IV or ejection fraction = 30% - Significant valvular disease - Planned coronary artery bypass surgery or percutaneous interventions - Any medical restriction to physical exercise - Severe medical illness or an acute health threatening disease (e.g., cancer) - Grade 3 hypertension (i.e., blood pressure = 180 systolic and/or 110 diastolic) - Severe mental illness requiring urgent psychiatric hospitalization or intervention, or risk of suicide - Alcohol or substance use disorder that would impede ability to complete study protocol - Ongoing psychological treatment |
Country | Name | City | State |
---|---|---|---|
Sweden | Karolinska University Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Karolinska University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse events | Potential adverse reactions to the treatment. Participants will be asked to report and rate | Baseline to 8 weeks | |
Other | Adverse events | Potential adverse reactions to the treatment. Participants will be asked to report and rate | Baseline to 8 months | |
Other | Adverse events | Potential adverse reactions to the treatment. Participants will be asked to report and rate | Baseline to 1 year and 2 months | |
Other | Adverse events | Potential adverse reactions to the treatment. Participants will be asked to report and rate | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment | |
Other | Accelerometer (Actigraf®) | n Accelerometer (Actigraf®) will be carried on the wrist over to measure physical activity over 1 week | Baseline to 8 weeks | |
Other | Accelerometer (Actigraf®) | n Accelerometer (Actigraf®) will be carried on the wrist over to measure physical activity over 1 week | Baseline to 1 year and 2 months | |
Other | Swedish Prescribed Drug Register | The prescription fill-rate of cardiovascular medication (e.g., statin)will be collected and will be used to calculate the proportion of days covered (PDC) with a statin. A PDC <80% will be used to indicate nonadherence as per convention in other studies of cardiovascular medication refills. | Retrospective period of 6 months at baseline | |
Other | Swedish Prescribed Drug Register | The prescription fill-rate of cardiovascular medication (e.g., statin)will be collected and will be used to calculate the proportion of days covered (PDC) with a statin. A PDC <80% will be | Retrospective period from 6 months at 6 month follow up | |
Other | Swedish Prescribed Drug Register | The prescription fill-rate of cardiovascular medication (e.g., statin)will be collected and will be used to calculate the proportion of days covered (PDC) with a statin. A PDC <80% will be | Retrospective period from 6 months at 12 month follow up | |
Other | Working Alliance Inventory | Measures therapeutic alliance with the psychologist | 2 weeks from baseline | |
Other | Treatment Credibility Scale | 2 weeks from baseline | Measures treatment credibility | |
Other | Client satisfaction Questionnaire | Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment. | Baseline to 8 weeks | |
Other | Follow-up questions on health changes | We will ask participant to describe if they have experienced any psychosocial stressors, changes in physical health, such as invasive therapy and changes of medication | Baseline to 8 weeks | |
Other | Follow-up questions on health changes | We will ask participant to describe if they have experienced any psychosocial stressors, changes in physical health, such as invasive therapy and changes of medication | Baseline to 8 months | |
Other | Follow-up questions on health changes | We will ask participant to describe if they have experienced any psychosocial stressors, changes in physical health, such as invasive therapy and changes of medication | Baseline to 1 year and 2 months | |
Other | AFFS/SCL-4 | 4 items derived from the Symptoms Checklist (SCL) and the Atrial Fibrillation Severity Scale (AFSS) measuring disabling cardiac symptoms | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment | |
Other | MI-behavior Questionnaire | 5 items measuring avoidance behavior from the MI-related avoidance questionnaire behaviors developed by the research group | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment | |
Other | DOSE Non-Adherence questionnaire | 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment | |
Primary | Cardiac anxiety questionnaire modified for weekly assessment | Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety. | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment [PRIMARY ENDPOINT] | |
Secondary | Cardiac anxiety questionnaire | Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety. | From baseline to 8 months | |
Secondary | Cardiac anxiety questionnaire | Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety. | From baseline to 1 year and 2 months | |
Secondary | HeartQoL Health-related Quality of Life Questionnaire modified for weekly assessment | The HeartQoL questionnaire, comprising 14 items, includes a Global scale of 14 items, further divided into Physical (10 items) and Emotional (4 items) subscales. Scores range from 0 to 3, with 3 indicating the highest level and 0 the lowest. | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment | |
Secondary | HeartQoL Health-related Quality of Life Questionnaire | The HeartQoL questionnaire, comprising 14 items, includes a Global scale of 14 items, further divided into Physical (10 items) and Emotional (4 items) subscales. Scores range from 0 to 3, with 3 indicating the highest level and 0 the lowest. | From baseline to 8 months | |
Secondary | HeartQoL Health-related Quality of Life Questionnaire | The HeartQoL questionnaire, comprising 14 items, includes a Global scale of 14 items, further divided into Physical (10 items) and Emotional (4 items) subscales. Scores range from 0 to 3, with 3 indicating the highest level and 0 the lowest. | From baseline to 1 year and 2 months | |
Secondary | Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease) modified for weekly assessment | Cardiac-related symptoms in two sub scales A) frequency: score ranging from 0-48, with higher score indicating higher frequency of symptoms, B) severity of experienced symptom: score ranging from 0- 48, with a higher score indicating more severe symptoms | From baseline to 8 weeks | |
Secondary | Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease) | cardiac-related symptoms in two sub scales A) frequency: score ranging from 0-48, with higher score indicating higher frequency of symptoms, B) severity of experienced symptom: score ranging from 0- 48, with a higher score indicating more severe symptoms | From baseline to 8 months | |
Secondary | Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease) | Cardiac-related symptoms in two sub scales A) frequency: score ranging from 0-48, with higher score indicating higher frequency of symptoms, B) severity of experienced symptom: score ranging from 0- 48, with a higher score indicating more severe symptoms | From baseline to 1 year and 2 months | |
Secondary | University of Toronto Atrial fibrillation Severity Scale (AFSS) | 3 item on cardiac-specific healthcare consumption. Scores ranges 0-15 with a higher score indicating more cardiac-related healthcare consumption | Baseline to 8 weeks | |
Secondary | University of Toronto Atrial fibrillation Severity Scale (AFSS) | 3 item on cardiac-specific healthcare consumption. Scores ranges 0-15 with a higher score indicating more cardiac-related healthcare consumption | From baseline to 8 months | |
Secondary | University of Toronto Atrial fibrillation Severity Scale (AFSS) | 3 item on cardiac-specific healthcare consumption. Scores ranges 0-15 with a higher score indicating more cardiac-related healthcare consumption | From baseline to 1 year and 2 months | |
Secondary | Myocardial infarction behavior questionnaire | MI-related avoidance questionnaire behaviors developed by the research group | From baseline to 8 weeks | |
Secondary | Myocardial infarction behavior questionnaire | MI-related avoidance questionnaire behaviors developed by the research group | From baseline to 8 months | |
Secondary | Myocardial infarction behavior questionnaire | MI-related avoidance questionnaire behaviors developed by the research group | From baseline to 1 year and 2 months | |
Secondary | DOSE Non-Adherence questionnaire | 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. | From baseline to 8 weeks | |
Secondary | DOSE Non-Adherence questionnaire | 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. | From baseline to 8 months | |
Secondary | DOSE Non-Adherence questionnaire | 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. | From baseline to 1 year and 2 months | |
Secondary | Perceived stress scale 4-item | Stress reactivity. A greater score indicate more perceived stress. | Baseline to 8 weeks | |
Secondary | Perceived stress scale 4-item | Stress reactivity. A greater score indicate more perceived stress. | Baseline to 8 months | |
Secondary | Perceived stress scale 4-item | Stress reactivity. A greater score indicate more perceived stress. | Baseline to 1 year and 2 months | |
Secondary | Short Fatigue questionnaire | 4-item scale measuring fatigue. | From baseline to 8 weeks | |
Secondary | Short Fatigue questionnaire | 4-item scale measuring fatigue. | Baseline to 8 months | |
Secondary | Short Fatigue questionnaire | 4-item scale measuring fatigue. | Baseline to 1 year and 2 months | |
Secondary | Patient Health Questionnaire-9 | Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression | From Baseline to 8 weeks | |
Secondary | Patient Health Questionnaire-9 | Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression | From Baseline to 8 months | |
Secondary | Patient Health Questionnaire-9 | Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression | From Baseline to 1 year and 2 months | |
Secondary | Insomnia Severity Index | Measurement of the degree of sleep difficulties. The total score can range from 0 to 28 points. Higher scores indicate more severe sleep difficulties. | From Baseline to 8 weeks | |
Secondary | Insomnia Severity Index | Measurement of the degree of sleep difficulties. The total score can range from 0 to 28 points. Higher scores indicate more severe sleep difficulties. | From Baseline to 8 months | |
Secondary | Insomnia Severity Index | Measurement of the degree of sleep difficulties. The total score can range from 0 to 28 points. Higher scores indicate more severe sleep difficulties. | From Baseline to 1 year and 2 months | |
Secondary | Perceived stress scale 4-item | Stress reactivity. A greater score indicate more perceived stress. | Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment | |
Secondary | The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity | Level of physical activity and inactivity: On the Godin leisure-time excercise: The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity. And from International Physical Activity Questionnaire we will use 1 item on inactivity | Baseline to 8 weeks | |
Secondary | The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity | Level of physical activity and inactivity: On the Godin leisure-time excercise: The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity. And from International Physical Activity Questionnaire we will use 1 item on inactivity | Baseline to 8 months | |
Secondary | The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity | Level of physical activity and inactivity: On the Godin leisure-time excercise: The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity. And from International Physical Activity Questionnaire we will use 1 item on inactivity | Baseline to 1 year and 2 months | |
Secondary | Lifestyle factors: The national Board of health and Welfare questionnaire | Questionnaire regarding diet (5 item), tobacco (2 item) and alcohol (3 item) diet (5 item), tobacco (2 item) and alcohol (3 item) and BMI. | Baseline to 8 weeks | |
Secondary | Lifestyle factors: The national Board of health and Welfare questionnaire | Questionnaire regarding diet (5 item), tobacco (2 item) and alcohol (3 item) diet (5 item), tobacco (2 item) and alcohol (3 item) and BMI. | Baseline to 8 months | |
Secondary | Lifestyle factors: The national Board of health and Welfare questionnaire | Questionnaire regarding diet (5 item), tobacco (2 item) and alcohol (3 item) diet (5 item), tobacco (2 item) and alcohol (3 item) and BMI. | Baseline to 1 year and 2 months | |
Secondary | Aversive cognition to medication | : A 3-item subset of questions with regards to psychological distress associated with cardiac medication | Baseline to 8 weeks | |
Secondary | Adversive cognition to medication | : A 3-item subset of questions with regards to psychological distress associated with cardiac medication | Baseline to 8 months | |
Secondary | Adversive cognition to medication | : A 3-item subset of questions with regards to psychological distress associated with cardiac medication | Baseline to 1 year and 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|